|
注册号: Registration number: |
ChiCTR2600121387 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-30 15:35:36 |
|
注册时间: Date of Registration: |
2026-03-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
探索不同类型子宫内膜异位病灶内靶点的表达,及其与月经周期、ASRM分期及临床因素的关系 |
|
Public title: |
To investigate the expression of target in different types of endometriotic lesions, and their associations with menstrual cycle, ASRM stage, and clinical factors |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
探索不同类型子宫内膜异位病灶内αvβ3 和 FAP 的表达,及其与月经周期、ASRM 分期及临床因素的关系 |
|
Scientific title: |
To explore the expression of αvβ3 and FAP in different types of endometriosis lesions, and their relationship with menstrual cycle, ASRM stage and clinical factors |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张蕾 |
研究负责人: |
张蕾 |
|
Applicant: |
Zhang Lei |
Study leader: |
Zhang Lei |
|
申请注册联系人电话: Applicant telephone: |
+86 186 0113 0459 |
研究负责人电话:
Study leader's |
+86 186 0113 0459 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
461458953@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
18601130459@btch.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市昌平区立汤路168号 |
研究负责人通讯地址: |
中国北京市昌平区立汤路168号 |
|
Applicant address: |
168 Litang Road, Changping District, Beijing, China |
Study leader's address: |
168 Litang Road, Changping District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京清华长庚医院 |
||
|
Applicant's institution: |
Beijing Tsinghua Changgung Hospital |
||
|
研究负责人所在单位: |
北京清华长庚医院 |
||
|
Affiliation of the Leader: |
Beijing Tsinghua Changgung Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
26154-4-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京清华长庚医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Beijing Tsinghua Changgung Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-13 00:00:00 | ||
|
伦理委员会联系人: |
刘曼婷 |
||
|
Contact Name of the ethic committee: |
Liu Manti |
||
|
伦理委员会联系地址: |
中国北京市昌平区立汤路168号 |
||
|
Contact Address of the ethic committee: |
168 Litang Road, Changping District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5611 8567 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京清华长庚医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Tsinghua Changgung Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国北京市昌平区立汤路168号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
168 Litang Road, Changping District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
子宫内膜异位症 |
||||||||||||||||||||||
|
Target disease: |
Endometriosis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
回顾性分析临床病例及组织标本,聚焦EM病灶与周围正常组织中靶点的表达差异,系统探讨临床及病理因素对其表达的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
Retrospective analysis of clinical cases and tissue specimens, focusing on the expression differences of target between endometriosis (EM) lesions and adjacent normal tissue, and systematically investigating the effects of clinical and pathological factors on their expression |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
合并恶性肿瘤的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients complicated with malignant tumors |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-02 00:00:00至 To 2027-02-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-02 00:00:00 至 To 2026-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
None |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |